News Incyte halts ph3 myelofibrosis study, unmet endpoint Incyte has made it clear that the recommendation to stop the study was not due to safety.
News 23andMe doses first patient in ph2a anti-tumour monotherapy Additionally, the company will be making investor presentations today and next week.
News Merck drops last phase 3 Keytruda trial in prostate cancer KEYNOTE-641 showed no benefit when added to Xtandi for castration-resistant prostate cancer.
News OCI-led CAR-T leukaemia therapy receives €2.5m from EIC New therapy for a mainly paediatric leukaemia won't require extraction of patient's own cells.
News Forget Merck, now Pfizer is said to be after Seagen Rumour of negotiations comes as Pfizer is facing a steep patent cliff in the next few years.
News J&J gets restricted label for PARP drug Akeega in EU Drug is backed for BRCA+ prostate cancer patients only, a narrower group than rival Lynparza.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
